About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The work of our group is mainly focused on personalized medicine, including chemical-functional stability studies of drugs in individualized preparations to be administered both orally and parenterally, as well as parenteral nutrition; research focused on the evaluation and/or design of population pharmacokinetic/pharmacodynamic (PK/PD) models and the characterization of the pharmacokinetics of certain drugs of therapeutic interest in the general population or in certain population groups; and research focused on pharmacogenetics and pharmacogenomics. Our research is also focused on advanced interventions: drug evaluation studies (effectiveness, safety and economic studies); and mobile health and telepharmacy.
IP: Investigació clínica observacional i experimental: Centrada en farmacogenètica o farmacogenòmica.
IP: Investigació clínica observacional i experimental: Centrada en l'avaluació de models PK/PD y caracterització PK de fàrmacs d'ele
IP: J. Bruno Montoro Ronsano
IP: David Berlana Martín
IP: Alba Pau Parra Collaborators: - Funding agency: SOCMIC Funding: 1500 Reference: SOCMIC/PAU/2023 Duration: 01/04/2022 - 01/06/2023
IP: Susana Clemente Bautista Collaborators: Maria José Cabañas Poy, Oscar Segarra Canton, Marina Álvarez Beltrán, Sonia García García Funding agency: Sociedad Española de Farmacia Hospitalaria Funding: 6240 Reference: 2021/SEFH/FARMACIA/CLEMENTE Duration: 06/09/2022 - 31/12/2024
IP: - Collaborators: - Funding agency: Sociedad Española de Farmacia Hospitalaria Funding: 4420 Reference: 2021/SEFH/FARMACIA/MIARONS Duration: 06/09/2022 - 05/09/2024
IP: Maria José Cabañas Poy Collaborators: - Funding agency: Sociedad Española de Farmacia Hospitalaria Funding: 14700 Reference: 2021/SEFH/FARMACIA/CABAÑAS Duration: 06/09/2022 - 21/11/2025
PhD student: Susana Clemente Bautista Director/s: Marta Miarons Font , Oscar Segarra Canton University: Universitat Autònoma de Barcelona Year: 2025
PhD student: Maria José Cabañas Poy Director/s: J. Bruno Montoro Ronsano, Félix Castillo Salinas University: Universitat de Barcelona Year: 2022
PhD student: Maria Josep Carreras Soler Director/s: Josep Tabernero Caturla University: Universidad Autònoma de Barcelona Year: 2020
Within the framework of a clinical trial, the first 3D printed medicine in Europe in the pediatric field will be tested.
